In clinical trials, participants lost up to 28.7% of their body weight
This means that food stays inside them for longer, contributing to the sense of fullness and this in turn contributes to peoples desire to eat less
Theyre just not saying it
[23] In the diseased brain, GLP-1 receptor agonist treatment is associated with protection against a range of experimental disease models such as Parkinson's disease, [24] [18] Alzheimer's disease, [25] [26] stroke, [24] traumatic brain injury, [14] [19] and multiple sclerosis
Clinical implication Although the association between GLP-1 RAs and gallbladder/biliary diseases has been supported by multiple studies, causality has not been definitively established
on the other hand, light exercise can naturally improve the Semaglutide hormonal balance